Doxazosin

How to order Doxazosin

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Doxazosin on Prescriptsy

Doxazosin is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Doxazosin is an alpha-1 adrenoceptor blocker used in the United Kingdom for two main indications: the treatment of essential hypertension (high blood pressure) and the management of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

It is available as standard immediate-release tablets and as modified-release (XL) tablets, both of which are prescription-only medicines available on the NHS.

Doxazosin works by relaxing smooth muscle in blood vessel walls and in the prostate and bladder neck, lowering blood pressure and improving urinary flow.

Hypertension affects approximately one in three adults in the UK and is the single largest modifiable risk factor for stroke, heart attack, heart failure, and chronic kidney disease.

Benign prostatic hyperplasia is extremely common in older men, with up to 80% of men over 70 experiencing some degree of prostatic enlargement and associated urinary symptoms.

Doxazosin provides effective treatment for both conditions, sometimes simultaneously in the same patient.

This page provides a comprehensive clinical overview of how doxazosin works, its licensed indications, dosing, expected timelines, side effects, important warnings, and how to obtain a prescription in the UK.

Important safety information about doxazosin

Before starting treatment, note the following key safety points.

• Doxazosin can cause a significant drop in blood pressure on first dose or dose increase (first-dose hypotension). Take the first dose at bedtime and stand up slowly from sitting or lying positions.
• Doxazosin may cause dizziness and drowsiness. Do not drive or operate machinery if affected, particularly at the start of treatment.
• If you are planning cataract surgery, inform your ophthalmologist that you are taking or have previously taken doxazosin. It can affect the behaviour of the iris during surgery.
• Modified-release tablets must be swallowed whole. Do not crush, chew, or divide them.
• Seek emergency medical attention if you experience a painful erection lasting more than 4 hours (priapism), as this requires urgent treatment.

Understanding hypertension and benign prostatic hyperplasia

Hypertension

Blood pressure is determined by the volume of blood the heart pumps and the resistance of the arteries to blood flow.

In hypertension, sustained elevation of systemic vascular resistance leads to chronically raised blood pressure.

Over time, this damages the lining of blood vessels (endothelium), promotes atherosclerosis, and increases the workload on the heart.

The threshold for diagnosing hypertension in the UK is a clinic reading of 140/90 mmHg or higher, confirmed by ambulatory or home monitoring (daytime average 135/85 mmHg or higher), in accordance with NICE guideline NG136.

Most hypertension is classified as essential (primary), meaning there is no single identifiable cause.

Risk factors include age, family history, obesity, high salt intake, physical inactivity, excessive alcohol consumption, and chronic stress.

Doxazosin is typically used as add-on therapy when first-line agents (ACE inhibitors, ARBs, calcium channel blockers, or thiazide-like diuretics) have not achieved target blood pressure.

Benign prostatic hyperplasia

The prostate gland surrounds the urethra just below the bladder in men.

With ageing, the prostate enlarges due to non-malignant proliferation of stromal and glandular tissue, a process influenced by dihydrotestosterone (DHT).

The enlarged prostate compresses the urethra, causing obstruction to urinary flow.

Symptoms include hesitancy (difficulty starting urination), weak stream, intermittent flow, incomplete emptying, increased frequency, urgency, and nocturia (waking at night to urinate).

These symptoms are collectively termed lower urinary tract symptoms (LUTS).

The obstruction in BPH has two components: a static component due to physical enlargement of the gland, and a dynamic component due to increased smooth muscle tone in the prostate capsule, stroma, and bladder neck, mediated by alpha-1 adrenoceptors.

Doxazosin targets the dynamic component by blocking these receptors and relaxing the smooth muscle.

How doxazosin works: mechanism of action

Doxazosin is a selective, long-acting alpha-1 adrenoceptor antagonist. It blocks the binding of noradrenaline to alpha-1 adrenoceptors on vascular smooth muscle cells and on smooth muscle cells in the prostate, bladder neck, and urethra.

In the cardiovascular system, alpha-1 blockade causes relaxation of arteriolar smooth muscle, reducing peripheral vascular resistance and lowering blood pressure.

Unlike some older non-selective alpha blockers, doxazosin does not cause significant reflex tachycardia because it has a gradual onset of action and does not block alpha-2 presynaptic receptors (which normally provide negative feedback on noradrenaline release).

The blood pressure-lowering effect develops smoothly over several hours, particularly with the modified-release formulation.

In the lower urinary tract, alpha-1A adrenoceptors predominate in the prostate and bladder neck smooth muscle.

By blocking these receptors, doxazosin reduces the dynamic (muscular) component of urethral obstruction, allowing the urethra to open more freely during urination.

This improves maximum urinary flow rate and reduces symptoms of hesitancy, straining, weak stream, and frequency. The onset of symptomatic improvement is typically within 1 to 2 weeks.

Doxazosin also has favourable metabolic effects. It modestly reduces total cholesterol, LDL cholesterol, and triglycerides, while slightly increasing HDL cholesterol. This lipid-modifying profile is a secondary benefit in patients with hypertension who often have concurrent dyslipidaemia.

Clinical evidence and UK prescribing guidance

Hypertension

NICE guideline NG136 (Hypertension in adults) recommends a stepwise approach to antihypertensive treatment.

Step 1 involves an ACE inhibitor or ARB (or a calcium channel blocker in patients over 55 or of Black African or Caribbean family origin).

Step 2 combines two agents. Step 3 adds a third agent (usually a thiazide-like diuretic).

Doxazosin is recommended as a step 4 add-on agent for resistant hypertension, defined as blood pressure not controlled on optimal doses of three drugs.

The ASCOT trial and subsequent analyses support the use of doxazosin GITS (gastrointestinal therapeutic system, equivalent to XL) as effective and well-tolerated add-on therapy.

Benign prostatic hyperplasia

NICE guideline NG231 (Lower urinary tract symptoms in men) recommends an alpha-1 blocker as first-line pharmacological treatment for moderate to severe LUTS associated with BPH.

Tamsulosin and alfuzosin are the most commonly prescribed alpha-1 blockers for BPH in the UK, but doxazosin is a well-established alternative, particularly useful when the patient also has hypertension, as it treats both conditions simultaneously.

For men with significant prostatic enlargement (above approximately 30 g or with a raised PSA), a 5-alpha reductase inhibitor (finasteride or dutasteride) may be added for long-term prostate volume reduction.

Dosage and administration

Hypertension

Immediate-release doxazosin: start at 1 mg once daily.

Increase at 1 to 2-week intervals to 2 mg, then 4 mg, then 8 mg, up to a maximum of 16 mg daily, according to blood pressure response and tolerability.

Modified-release doxazosin (XL): start at 4 mg once daily. Increase to 8 mg after at least 4 weeks if blood pressure remains above target.

Benign prostatic hyperplasia

Immediate-release doxazosin: start at 1 mg once daily. Titrate as for hypertension up to a maximum of 8 mg once daily. Modified-release: start at 4 mg, increase to 8 mg if needed.

Practical advice

Take doxazosin at a consistent time each day. The first dose (and any dose increases) should be taken at bedtime to reduce the risk of first-dose hypotension. Swallow modified-release tablets whole with water; do not crush, chew, or divide them.

If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose.

If you miss several consecutive doses, consult your prescriber before restarting, as retitration may be necessary.

Side effects of doxazosin

Common side effects

Dizziness, headache, fatigue, and peripheral oedema (ankle swelling) are the most commonly reported side effects.

Postural hypotension (a feeling of light-headedness or faintness on standing up) is common, particularly at the start of treatment and after dose increases.

Drowsiness, nausea, and nasal congestion (rhinitis) are also reported. These effects typically improve as the body adjusts to the medication over the first few weeks.

Uncommon side effects

Less commonly reported effects include urinary incontinence (especially stress incontinence in women), dry mouth, vertigo, palpitations, chest pain, abdominal pain, diarrhoea, constipation, muscle cramps and pain, and nosebleeds. Blurred vision and tinnitus have also been reported.

Rare but serious side effects

Priapism (a prolonged, painful erection lasting more than 4 hours) is a rare but serious adverse effect requiring emergency treatment to prevent permanent penile damage.

Seek immediate medical attention at A&E if this occurs. Intraoperative floppy iris syndrome (IFIS) during cataract surgery has been reported. Rare hepatic effects include cholestatic jaundice and hepatitis.

Blood disorders including thrombocytopenia and leucopenia are very rare.

When to seek medical advice

Contact your GP or NHS 111 if you experience persistent dizziness, significant ankle swelling, or urinary incontinence that affects your daily life.

Seek emergency medical attention (call 999 or attend A&E) for priapism, collapse, or signs of a severe allergic reaction (difficulty breathing, facial or throat swelling).

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

First-dose hypotension

The most important practical warning is the risk of first-dose hypotension.

This is a significant drop in blood pressure that can occur within 2 to 6 hours of the first dose, causing dizziness, light-headedness, or fainting.

It is more likely in patients who are volume depleted (for example from diuretic use or inadequate fluid intake), elderly, or taking other blood pressure-lowering medications.

The modified-release formulation reduces this risk by delivering the drug more gradually, but caution is still advised when initiating therapy.

Cataract surgery

Intraoperative floppy iris syndrome (IFIS) is a recognised complication of cataract surgery in patients taking or who have previously taken alpha-1 blockers.

The iris becomes atonic during surgery, prolapsing through incisions and complicating the procedure. If you are planning cataract surgery, inform your ophthalmologist.

Stopping doxazosin before surgery has not been shown to reliably prevent IFIS, and the decision about continuing or stopping should be made jointly by the prescriber and the surgeon.

Hepatic impairment

Doxazosin is extensively metabolised by the liver. Use with caution in mild to moderate hepatic impairment, with slower dose titration and careful monitoring. Avoid use in severe hepatic impairment.

Drug interactions

Doxazosin may interact with other antihypertensive medications, increasing the risk of excessive blood pressure reduction.

PDE5 inhibitors (sildenafil, tadalafil, vardenafil) used for erectile dysfunction can cause additive hypotension; patients should be stable on doxazosin before starting a PDE5 inhibitor at a low dose.

NSAIDs may reduce the antihypertensive effect. Beta-blockers used concurrently may occasionally worsen first-dose hypotension.

Doxazosin compared with other alpha-1 blockers

Several alpha-1 blockers are available in the UK.

Tamsulosin is the most commonly prescribed for BPH, as it has greater selectivity for alpha-1A adrenoceptors in the prostate and is less likely to cause systemic hypotension.

However, tamsulosin does not lower blood pressure significantly and is not licensed for hypertension. Alfuzosin is another option for BPH.

Prazosin, an older alpha-1 blocker, is used for hypertension and Raynaud phenomenon but requires multiple daily doses.

Doxazosin's advantage lies in its once-daily dosing, its dual indication for both hypertension and BPH, and its availability in modified-release form for smoother blood pressure control.

How to get a doxazosin prescription in the UK

Doxazosin is a prescription-only medicine available through the NHS.

For hypertension, it is typically prescribed by your GP as add-on therapy when other antihypertensives have not achieved adequate control.

For BPH, it may be initiated by a GP or a urologist following assessment of symptoms, prostate examination, and relevant investigations (including PSA testing and uroflowmetry where appropriate).

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) may also prescribe doxazosin following a structured clinical assessment.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Sources

• Doxazosin 4 mg Tablets, Summary of Product Characteristics (EMC)
• Doxazosin, British National Formulary (BNF)
• NICE NG136: Hypertension in adults
• NICE NG231: Lower urinary tract symptoms in men
• Doxazosin, NHS
• MHRA Yellow Card Scheme